Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2008

Open Access 01-12-2008 | Case report

Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report

Authors: Hideki Kimura, Toshihiko Iizasa, Aki Ishikawa, Mitsuru Yoshino, Masato Shingyouji, Masaki Kimura, Tetushi Hirata, Akiko Odaka, Keiko Matsubayasi

Published in: Journal of Medical Case Reports | Issue 1/2008

Login to get access

Abstract

Introduction

Malignant ascites is often a sign of a terminal stage in several malignant diseases. To control ascites, drainage and intra-abdominal chemotherapy are often used in those patients but eradication of ascites is difficult and prognosis is poor.

Case presentation

A 55-year-old woman was admitted to our hospital on 26 January 2007 with dyspnea, abdominal distention and oliguria. Abdominocentesis revealed peritoneal carcinomatosis resulting from abdominal recurrence from lung cancer. To alleviate the dyspnea and abdominal distention, we drained the ascites aseptically and infused them intravenously back into the patient after removal of tumor cells by centrifugation, and then concentration by apheresis. After the drainage of ascites, we intraperitoneally infused activated killer cells and dendritic cells from the patient's tumor-draining lymph nodes, together with 4.5 × 105U interleukin-2 in 50 ml saline by 2.1 ml/hour infuser balloon.
Drastic decreases in the tumor cell count and in ascite retention were observed after several courses of ascites drainage, intravenous infusion and intraperitoneal immunotherapy. The plasma protein level was maintained during the treatment notwithstanding the repeated drainage of ascites. Cell surface marker analysis, cytotoxic activities against autologous tumor cells and interferon-gamma examination of ascites suggested the possibility that these effects were mediated by immunological responses of activated killer cells and dendritic cells infused intraperitoneally.

Conclusion

Combination of local administration of immune cells and infusion of concentrated cell free ascites may be applicable for patients afflicted with refractory ascites.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kianmanesh R, Scaringi S, Sabate J-M, Castel B, Pons-Kerjean N, Coffin B, Hay J-M, Flamant Y, Msika S: Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. Ann Surg. 2007, 245 (4): 597-603. 10.1097/01.sla.0000255561.87771.11.CrossRefPubMedPubMedCentral Kianmanesh R, Scaringi S, Sabate J-M, Castel B, Pons-Kerjean N, Coffin B, Hay J-M, Flamant Y, Msika S: Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. Ann Surg. 2007, 245 (4): 597-603. 10.1097/01.sla.0000255561.87771.11.CrossRefPubMedPubMedCentral
2.
go back to reference Elias D, Blot F, Otmany A, Antoun S, Lasser P, Boige V, Rougier P, Ducreux M: Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer. 2001, 92 (1): 71-76. 10.1002/1097-0142(20010701)92:1<71::AID-CNCR1293>3.0.CO;2-9.CrossRefPubMed Elias D, Blot F, Otmany A, Antoun S, Lasser P, Boige V, Rougier P, Ducreux M: Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer. 2001, 92 (1): 71-76. 10.1002/1097-0142(20010701)92:1<71::AID-CNCR1293>3.0.CO;2-9.CrossRefPubMed
3.
go back to reference Gilly FN, Beaujard A, Glehen O, Grandclement E, Caillot JL, Francois Y, Sadeghi-Looyeh B, Gueugniaud PY, Garbit F, Benoit M, Bienvenu J, Vignal J: Peritonectomy combined with intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis. Anticancer Res. 1999, 19 (3B): 2317-2321.PubMed Gilly FN, Beaujard A, Glehen O, Grandclement E, Caillot JL, Francois Y, Sadeghi-Looyeh B, Gueugniaud PY, Garbit F, Benoit M, Bienvenu J, Vignal J: Peritonectomy combined with intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis. Anticancer Res. 1999, 19 (3B): 2317-2321.PubMed
4.
go back to reference Glehen O, Mithieux F, Osinsky D, Beaujard AC, Freyer G, Guertsch P, Francois Y, Peyrat P, Panteix G, Vignal J, Gilly FN: Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol. 2003, 21 (5): 799-806. 10.1200/JCO.2003.06.139.CrossRefPubMed Glehen O, Mithieux F, Osinsky D, Beaujard AC, Freyer G, Guertsch P, Francois Y, Peyrat P, Panteix G, Vignal J, Gilly FN: Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol. 2003, 21 (5): 799-806. 10.1200/JCO.2003.06.139.CrossRefPubMed
5.
go back to reference Sugarbaker PH: Strategies for the prevention and treatment of peritoneal carcinomatosis from gastrointestinal cancer. Cancer Invest. 2005, 23 (2): 155-172. 10.1081/CNV-200050478.CrossRefPubMed Sugarbaker PH: Strategies for the prevention and treatment of peritoneal carcinomatosis from gastrointestinal cancer. Cancer Invest. 2005, 23 (2): 155-172. 10.1081/CNV-200050478.CrossRefPubMed
6.
go back to reference Sugarbaker PH: New responsibilities in the management of colorectal cancer with peritoneal seeding. Cancer Invest. 2002, 20 (7–8): 1118-1122. 10.1081/CNV-120005929.CrossRefPubMed Sugarbaker PH: New responsibilities in the management of colorectal cancer with peritoneal seeding. Cancer Invest. 2002, 20 (7–8): 1118-1122. 10.1081/CNV-120005929.CrossRefPubMed
7.
go back to reference Kimura H, Dobrenkov K, Iida T, Suzuki M, Ando S, Yamamoto N: Tumor-draining lymph nodes of primary lung cancer patients: A potent source of tumor-specific killer cells and dendritic cells. Anticancer Res. 2005, 25: 85-94.PubMed Kimura H, Dobrenkov K, Iida T, Suzuki M, Ando S, Yamamoto N: Tumor-draining lymph nodes of primary lung cancer patients: A potent source of tumor-specific killer cells and dendritic cells. Anticancer Res. 2005, 25: 85-94.PubMed
Metadata
Title
Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report
Authors
Hideki Kimura
Toshihiko Iizasa
Aki Ishikawa
Mitsuru Yoshino
Masato Shingyouji
Masaki Kimura
Tetushi Hirata
Akiko Odaka
Keiko Matsubayasi
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2008
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/1752-1947-2-372

Other articles of this Issue 1/2008

Journal of Medical Case Reports 1/2008 Go to the issue